AI generated
Aug 11, 2026, 13:34
Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
Brett Hoover, Senior Director of Global Project Management, Medical Imaging and Specialty Solutions at Clario, shared a post on LinkedIn:
“New CCTA Study Suggests that Current Plaque is the Key Biomarker for Assessing major adverse cardiovascular events (MACE) risk.
Emerging research demonstrates that those with total plaque volume more than 750 mm3 have an 18.6 percent risk of MACE at four years in comparison to a 1.4 percent MACE risk for those with no plaque.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring
-
Aug 11, 2026, 14:30Bharat Moyal: The New KDIGO 2026 Approach to Anemia in CKD
-
Aug 11, 2026, 14:16Rayan Ahmed: Master Blood Films and Pathology Online
-
Aug 11, 2026, 13:53Steven Lubega: Why Are Healthy Newborns Born Poorly Equipped To Stop Bleeding?
-
Aug 11, 2026, 13:47Why Stroke Risk Changes During Pregnancy – International Journal of Stroke
-
Aug 11, 2026, 13:43Moyahabo Julius Rampya: Shaping the Future of Stroke Care in Africa
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India